Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.

The challenge for internal therapy is to deliver the highest possible dose to the tumor while sparing normal organs from damage. Currently, the potential risk of kidney and red marrow toxicity limits the amount of radioactivity that may be administered. An accurate dosimetry method that would provide reliable dose estimates to these critical organs and to tumors before therapy would allow the clinician to plan a specific therapeutic regimen and also select those patients who would benefit the most from treatment. The dosimetry for (90)Y-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide is usually based on quantitative imaging at different time points that provides information on activity retention in organs over time and on stylized models representing average individuals. Because the therapeutic agent labeled with (90)Y is not suitable for quantitative imaging, the peptide surrogate labeled with the positron emitter (86)Y can be considered the most appropriate tracer for measuring distribution and retention of the radiopharmaceutical over time. Dose calculations in target organs are generally performed using the MIRDOSE program, in which S values from source to target are integrated. Significant improvement of dose estimates may be achieved by introducing patient-specific adjustments to the standard models. The use of individual kidney volumes assessed by CT instead of the use of a fixed volume for males and females may significantly improve the determination of kidney radiation doses. The use of actual CT-derived tumor volumes has also shown a dose-efficacy relationship. Additional improvements in this field include the validation and use of an (111)In surrogate to avoid the complexity of (86)Y use and the consideration of radiobiologic parameters, such as fractionation effects and the specific biologic efficacy of internally deposited radiation, which are probably underestimated using currently available methods.

[1]  P Lambin,et al.  Low-dose hypersensitivity: current status and possible mechanisms. , 2001, International journal of radiation oncology, biology, physics.

[2]  David M. Goldenberg,et al.  Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations , 1998, European Journal of Nuclear Medicine.

[3]  S. Shen,et al.  Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  S. Weiner,et al.  End-stage renal disease after treatment with 90Y-DOTATOC , 2001, European Journal of Nuclear Medicine.

[5]  H. Herzog,et al.  Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide , 2001, European Journal of Nuclear Medicine.

[6]  M. Konijnenberg,et al.  Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients? , 2003, Cancer biotherapy & radiopharmaceuticals.

[7]  D. Piwnica-Worms MIRDOSE: Personal Computer Software for Internal Dose Assessment in Nuclear Medicine , 1996 .

[8]  Marion de Jong,et al.  Low-dose-rate irradiation by 131I versus high-dose-rate external-beam irradiation in the rat pancreatic tumor cell line CA20948. , 2004, Cancer biotherapy & radiopharmaceuticals.

[9]  G. Denardo,et al.  Prediction of myelotoxicity using semi-quantitative marrow image scores. , 1997, Journal of Nuclear Medicine.

[10]  K. Eckerman,et al.  Contribution to red marrow absorbed dose from total body activity: a correction to the MIRD method. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  M. Cremonesi,et al.  Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Henry I. Kohn,et al.  Sources, Effects and Risks of Ionizing Radiation , 1989 .

[13]  H. V. van Boven,et al.  Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[15]  J. Reubi,et al.  Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.

[16]  L. Kvols,et al.  86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  A. Todd-Pokropek,et al.  Scatter correction in scintigraphy: the state of the art , 1994, European Journal of Nuclear Medicine.

[18]  M. Béhé,et al.  Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. , 2002, Cancer biotherapy & radiopharmaceuticals.

[19]  E. Nitzsche,et al.  Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  M. Cremonesi,et al.  Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: The experience of the European Institute of Oncology Group , 2002 .

[21]  L. Travaini,et al.  Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-Octreotide: Implications for internal radiotherapy with 90Y-DOTATOC , 2000 .

[22]  S. Walrand,et al.  Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86 , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  Y. Erdi,et al.  Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. , 2000, Medical physics.

[24]  H. Saji,et al.  Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo. , 1998, Bioconjugate chemistry.

[25]  J. Mueller‐Brand,et al.  Yttrium-90-labelled somatostatin-analogue for cancer treatment , 1998, The Lancet.

[26]  George Sgouros,et al.  MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  M. Stabin Developments in the internal dosimetry of radiopharmaceuticals. , 2003, Radiation protection dosimetry.

[28]  R. Valkema,et al.  Radiolabelled peptides for tumour therapy: current status and future directions , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  F. Orsi,et al.  Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: implications for internal radiotherapy with 90Y-DOTATOC , 1999, European Journal of Nuclear Medicine.

[30]  S. Finch Radiation-induced leukemia. , 2001, Blood.

[31]  L. Kvols,et al.  Safety and efficacy of [Y-90-DOTA,Tyr(3)]-octreotide (Y-90-SMT487; OctreoTher) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study , 2001 .

[32]  H. Herzog,et al.  PET imaging with yttrium-86: comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  K. Eckerman,et al.  Evolution and status of bone and marrow dose models. , 2002, Cancer biotherapy & radiopharmaceuticals.

[34]  L. Kvols,et al.  Tumor dosimetry based on PET Y-86-DOTA-Tyr3-octreotide (SMT487) and CT-scan predicts tumor response to Y-90-SMT487 (OctreoTher (TM)) therapy. , 2000 .

[35]  M. Mihatsch,et al.  A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[36]  A. Eberle,et al.  Receptor targeting for tumor localisation and therapy with radiopeptides. , 2000, Current medicinal chemistry.

[37]  岩崎 民子 SOURCES AND EFFECTS OF IONIZING RADIATION : United Nations Scientific Committee on the Effects of Atomic Radiation UNSCEAR 2000 Report to the General Assembly, with Scientific Annexes , 2002 .

[38]  M G Stabin,et al.  MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  Larson,et al.  Quantitative Imaging of Yttrium-86 with PET. The Occurrence and Correction of Anomalous Apparent Activity in High Density Regions. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[40]  R. Valkema,et al.  Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. , 2002, Seminars in nuclear medicine.